Companies previously delayed vaccine programme in December 2020
Companies previously delayed vaccine programme in December 2020
Joint venture, MedX, will provide teleradiology reporting services
Agreement will aim to accelerate development of next-generation NK cell therapies
Services will be offered to staff who have been affected by the COVID-19 pandemic
Decision made in consultation with the FDA following disappointing trial results
AVA6000 is pro-drug form of the chemotherapy doxorubicin, modified using Avacta’s pre|CISION chemistry
A range of Facebook frames and Instagram GIFs will be ready for use on social media today
Exscientia will use its AI-driven technology to generate novel clinical assets targeting neuroinflammation
New agreement builds on existing collaboration to develop therapies for coronaviruses
New report recommends continuing collaborations across the life sciences sector
In the HER2CLIMB trial, Tukysa-treated patients had a 46% reduction in the risk of cancer progression or death
Series C financing will also be used for the development of Evox’s DeliverEX exosome drug platform
Funding will be given to four long COVID research studies
New data shows overuse of SABA relievers is responsible for 250,000 tonnes of CO2 emissions annually
Study is investigating company’s lead asset SFX-01